Tadalafil vs Udenafil
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Pulmonary Arterial Hypertension
Shared mechanism: PDE5 · full Pulmonary Arterial Hypertension pipeline
Tadalafil · Adcirca
Marketed by Eli Lilly and partners
NCT00549302 · Phase 3 · completed
This trial continued participants who had already been randomized in an earlier placebo-controlled study rather than randomizing a new population, and its own primary outcome was a pooled safety tally without a placebo comparator, so it provides supportive long-term evidence rather than a fresh controlled demonstration of efficacy. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Adverse Events (AEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: May 2028 · NCT06968962 (registry estimate)
Reported efficacy
Period 1: Change From Baseline to Week 24 in a 6 Minute Walk (MW) Distance in Meters (Baseline, Week 24): 6-minute walk distance change from baseline at Week 24: LS mean 60.48 m (SE 20.41) tadalafil vs 36.60 m (SE 20.78) placebo; placebo-adjusted mean difference 23.88 m (SD 29.11) (missed)
Result source: NCT01824290
Udenafil · Zydena
Marketed by Dong-A ST and partners
NCT02304198 · Phase 2/3 · completed
The study was an open-label, single-group continuation of the randomized DA8159_PAH_II trial, with 59 participants and no concurrent placebo or active comparator. Its registered primary outcome on ClinicalTrials.gov is "Safety (Adverse Events, Physical Examination, Vital Sign, Electrocardiography, Laboratory test, etc)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
Results for Pulmonary Arterial Hypertension
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Udenafil: no structured comparison results are available for Pulmonary Arterial Hypertension.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tadalafil
show 7 more results
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 1 further endpoint in the CSV export.
Available safety results
Tadalafil
| Dropout rate | 18%40 mg NCT00549302 · Phase 3 show 7 more results4% NCT01042158 · Phase 4 · registry result, not featured evidence · combination 20.5%Combination Therapy: Ambrisentan + NCT01178073 · Phase 3 · registry result, not featured evidence · combination 30.5%Tadalafil Monotherapy NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy 0%Heavy Weight: ≥40 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence 0%Light Weight <25 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence —Light Weight: <25 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence 0%Middle Weight: 25 kg to <40 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | 5.4%40 mg NCT00549302 · Phase 3 show 7 more results— NCT01042158 · Phase 4 · registry result, not featured evidence · combination 11.3%Combination Therapy: Ambrisentan + NCT01178073 · Phase 3 · registry result, not featured evidence · combination 15.9%Tadalafil Monotherapy NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy —Heavy Weight: ≥40 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence —Light Weight <25 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence —Light Weight: <25 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence —Middle Weight: 25 kg to <40 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | —40 mg NCT00549302 · Phase 3 show 7 more results12.5% NCT01042158 · Phase 4 · registry result, not featured evidence · combination 41.1%Combination Therapy: Ambrisentan + NCT01178073 · Phase 3 · registry result, not featured evidence · combination 45%Tadalafil Monotherapy NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy 50%Heavy Weight: ≥40 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence —Light Weight <25 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence 16.7%Light Weight: <25 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence 57.1%Middle Weight: 25 kg to <40 kg NCT01484431 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | oedema peripheral 44% headache 41.1% diarrhoea 20.9% NCT01178073 · Phase 3 · registry result, not featured evidence · combination show 4 more resultsheadache 36.4% oedema peripheral 29.1% dyspnoea 18.5% NCT01178073 · Phase 3 · registry result, not featured evidence · monotherapy angina pectoris 33.3% ear pain 33.3% headache 33.3% NCT01484431 · Phase 1/2 · registry result, not featured evidence gastroenteritis 50% bronchitis 33.3% ecchymosis 33.3% NCT01484431 · Phase 1/2 · registry result, not featured evidence oropharyngeal pain 42.9% headache 28.6% pain in extremity 28.6% NCT01484431 · Phase 1/2 · registry result, not featured evidence |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Tadalafil's landscape · Udenafil's landscape